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In Brief
Glucagon is secreted from pancreatic a
cells in hypoglycemic conditions. Briant
et al. demonstrate that this response is
fueled by fatty acid oxidation. The energy
generated by oxidation is used to
maintain membrane potential dynamics,
action potential morphology, and Na+-K+
pump activity.
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https://doi.org/10.1016/j.celrep.2018.05.035SUMMARY
Glucagon, the principal hyperglycemic hormone,
is secreted from pancreatic islet a cells as part of
the counter-regulatory response to hypoglycemia.
Hence, secretory output from a cells is under high
demand in conditions of low glucose supply. Many
tissues oxidize fat as an alternate energy substrate.
Here, we show that glucagon secretion in low
glucose conditions is maintained by fatty acid
metabolism in both mouse and human islets, and
that inhibiting this metabolic pathway profoundly
decreases glucagon output by depolarizing a cell
membrane potential and decreasing action potential
amplitude. We demonstrate, by using experimental
and computational approaches, that this is not
mediated by the KATP channel, but instead due to
reduced operation of the Na+-K+ pump. These
data suggest that counter-regulatory secretion of
glucagon is driven by fatty acid metabolism, and
that the Na+-K+ pump is an important ATP-depen-
dent regulator of a cell function.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a metabolic disorder charac-
terized by hyperglycemia, insulin resistance, and insufficient
insulin secretion from islet b cells (Leahy, 2005). However, it is
becoming increasingly apparent that over-secretion of glucagon
from pancreatic a cells also contributes to the increased hepatic
glucose production and associated hyperglycemia in T2DM. The
abnormalities in glucagon secretion in T2DM include both loss of
adequate suppression under hyperglycemic conditions (Cryer,
2002, 2008; Cryer et al., 2003; Dunning et al., 2005; D’Alessio,
2011; Unger and Cherrington, 2012) and insufficient release3300 Cell Reports 23, 3300–3311, June 12, 2018 ª 2018 The Author(
This is an open access article under the CC BY license (http://creativeduring episodes of hypoglycemia (Gerich et al., 1973; Bolli and
Perriello, 1990; Shamoon et al., 1994).
Despite the centrality of glucagon in the etiology of T2DM, the
mechanisms by which glucagon secretion is regulated at low
glucose have not been fully elucidated. Several paracrine pro-
cesses have been demonstrated to alter glucagon secretion
(Gromada et al., 2007; Gylfe, 2013, 2016; Caicedo, 2013; Gylfe
and Gilon, 2014). However, in low glucose, glucagon secretion
is controlled by mechanisms intrinsic to the a cell (Vieira et al.,
2007; Zhang et al., 2013).
The b cell is tailored to deal with conditions of high glucose: the
high-Km GLUT transporter (GLUT2), high-Km glucokinase, and
high respiratory capacity in b cells result in a robust insulin secre-
tory response to hyperglycemia (Heimberg et al., 1995, 1996;
Dı´az et al., 2007). In the a cell, glucokinase activity (Heimberg
et al., 1996) and glycolytic flux (Heimberg et al., 1995) are compa-
rable with that of b cells. However, glucose oxidation (Schuit
et al., 1997; Detimary et al., 1998), as well as glucose-induced
ATP (Detimary et al., 1998; Ishihara et al., 2003; Ravier andRutter,
2005; Li et al., 2015), FADH2 (Quesada et al., 2006), and NAD(P)H
(Quoix et al., 2009) production are all lower in a cells. Despite
a cells having a lower capacity to produce ATP in response to
glucose, a cells are still able to retain secretory function at low
or even in the complete absence of glucose (De Marinis et al.,
2010; Olsen et al., 2005; Salehi et al., 2007; Vieira et al., 2007).
Some tissues have an obligatory need for glucose as an en-
ergy substrate (Be´langer et al., 2011). However, many tissues
in the body act as ‘‘omnivores’’ using a variety of carbon sub-
strates as energy sources to sustain sufficient ATP generation.
b-oxidation of free fatty acids (FFAs) is a major energy source in
the heart (Most et al., 1969; Lopaschuk et al., 2010), muscle
(Rasmussen et al., 2002), and liver (Ontko, 1972). In the islet,
FFAs are known to regulate glucose-induced insulin secretion
independently of b-oxidation via G-protein-coupled receptor
GPR40 signaling (Itoh et al., 2003). In the a cell, less is known
about the role of FFAs in regulating glucagon secretion.
Although short-term exposure to supra-physiological levels ofs).
commons.org/licenses/by/4.0/).
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Figure 1. Blocking FFA Transport Pharma-
cologically or by CPT1a Knockdown Re-
duces Glucagon Secretion in Mouse a Cells
and aTC1-6 Cells
(A) Glucagon secretion from WT mouse islets at 1
and 10 mM glucose with or without etomoxir
(100 mM) reduced glucagon secretion (n = 3 mice).
(B) ATP production in WT mouse islets during
exposure to 1 or 10 mM glucose, as well as 1 mM
glucose and etomoxir (100 mM) (n = 4 mice).
(C) Glucagon secretion from aTC1-6 cells at 1 and
10 mM glucose with or without etomoxir (100 mM)
(n = 3).
(D) b-Oxidation measured using [3H]palmitate in
aTC1-6 cells at 1 and 10 mM glucose with or
without etomoxir (100 mM) (n = 6 observations,
from 2 experiments).
All data are represented as mean ± SEM. Paired
t test with Tukey post hoc or two-way ANOVA
with Student-Newman-Keuls post hoc; *p < 0.05.
See also Figure S1.FFA have been demonstrated to increase glucagon secretion
(Olofsson et al., 2004), this may be due to GPR40 signaling
(Kristinsson et al., 2017), rather than b-oxidation. Circulating
FFAs are essential for maintaining systemic energy homeo-
stasis during hypoglycemia (Hue and Taegtmeyer, 2009).
Given that b-oxidation of FFAs can provide substantial
amounts of ATP, it may be that a cells utilize this energy source,
oxidizing FFAs to maintain secretory function in conditions of
hypoglycemia.
Here, we show that the oxidation of long-chain FFAs in a cells
contributes to maintaining glucagon secretion under hypoglyce-
mic conditions. We also provide a mechanism by which fatty
acid oxidation (FAO) energizes glucagon secretion in counter-
regulatory conditions.
RESULTS
Glucagon Secretion from Mouse a Cells Depends on
FAO
We first explored the dependence of glucagon secretion under
hypoglycemic conditions on FAO (Figure 1). Carnitine palmitoyl-
transferase 1 (CPT1) is a mitochondrial transmembrane enzyme
responsible for the formation of acyl-carnitine from long-chain
acyl-coenzyme A’s (CoA), which can subsequently be trans-
ported into the mitochondria and used for b-oxidation. This
enzyme is considered rate limiting for b-oxidation of long-chain
fatty acids (LCFAs; Kim et al., 2000; Stephens et al., 2007).
When mouse islets were exposed to low (1 mM) glucose, phar-
macological blockade of CPT1 with etomoxir (100 mM) reduced
glucagon secretion by 40% (p < 0.001; Figure 1A) and
decreased the cytoplasmic ATP/ADP ratio (p < 0.0001;
Figure 1B). This was via a direct effect on a cells, because
insulin signaling was not altered (p = 0.84; Figure S1). EtomoxirCell Realso reduced glucagon secretion by
40% in aTC1-6 cells at 1 mM glucose
(p = 0.005; Figure 1C). This was due to a
40% reduction in b-oxidation (p =
0.017; Figure 1D). These data show that FAO contributes to
glucagon secretion in hypoglycemic conditions.
CPT1a is Essential for Fat Oxidation and Glucagon
Secretion in a Cells
We investigated the expression of CPT1 in a cells and found a
high degree of co-localization between glucagon and the liver
CPT1 isoform (CPT1a) in wild-type (WT) mouse islets (Figure 2A).
The muscle CPT1 isoform (CPT1b) is also known to be ex-
pressed in a cells, but to a lower degree than CPT1a (Benner
et al., 2014). Knockdown of Cpt1a in aTC1-6 cells (40% reduced
protein content; Figure 2B) resulted in a decrease in glucagon
secretion (p = 0.003; Figure 2C) and b-oxidation (p = 0.033; Fig-
ure 2D) at 1 mM glucose, consistent with our pharmacological
blockade of CPT1 with etomoxir (Figure 1).
The aTC1-6 cell line is an artificial system, and so to under-
stand the implications of reduced CPT1a expression in
whole islets, we generated an a cell-specific Cpt1a knockout
(aCPT1a-KO) mouse. Islets from these mice have no CPT1a
expression in 85% ± 2% of the a cells (Figures 2E and 2F).
Knockout of Cpt1a reduced glucagon secretion by 40% at
1 mM glucose (p < 0.001; Figure 2H), without affecting glucagon
content (p = 0.937; Figure 2G) or glucagon secretion at 10 mM
glucose (p = 0.64; Figure 2H). Insulin secretion was not affected
by the loss of Cpt1a in a cells (p = 0.43; Figure S1B). Blood
glucose is unlikely to reach 1 mM in vivo; therefore, we investi-
gated glucagon secretion in situ from control and aCPT1a-KO
by perfusion of the whole pancreas with 4, 6, and 10 mM
glucose. Glucagon secretion from aCPT1a-KO was significantly
lower compared with control mice (p = 0.003; Figures 2I and 2J),
and only control mice responded by significantly lowering
glucagon secretion in response to 10 mM glucose (p = 0.045;
Figures 2I and 2J). These data suggest that Cpt1a knockoutports 23, 3300–3311, June 12, 2018 3301
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Figure 2. Knockout of CPT1a Specifically in a Cells Reduces Glucagon Secretion
(A) Immunofluorescence for glucagon (red) and CPT1a (green) in WT mouse islets from pancreatic slides. Scale bar, 50 mM.
(B) Knockdown (KD) of CPT1a in aTC1-6 cells treated with either scrambled small interfering RNA (siRNA; control) or siRNA targeting Cpt1a mRNA (note the
40% reduction) (n = 6 observations from 3 experiments).
(C) Glucagon secretion in aTC1-6 cells at 1 and 10 mM glucose treated with either scrambled siRNA (control) or siRNA targeting Cpt1a mRNA (n = 3).
(D) b-Oxidation measured using [3H]palmitate in aTC1-6 cells at 1 and 10 mM glucose treated with either scrambled siRNA (control) or siRNA targeting Cpt1a
mRNA (n = 6 observations, from 2 experiments).
(E) Immunofluorescent detection of glucagon (red) and CPT1a (green) in isolated islets from a cell-specific knockout ofCpt1a (aCPT1a-KO) and littermate control
mice. Scale bar, 50 mM (n = 5).
(F) Percentage (%) of cells that show co-localization of CPT1a and glucagon in aCPT1a-KO mice (n = 5 islets, 3 mice, 145 cells).
(G) Glucagon content in isolated islets from control and aCPT1a-KO (KO) islets (n = 6).
(H) Glucagon secretion from isolated islets from control and aCPT1a-KO mice at 1 and 10 mM glucose (n = 6).
(legend continued on next page)
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Figure 3. Cpt1a Knockout Reduces Fasting
Plasma Glucose
(A) Plasma glucose in fed control and aCPT1a-KO
(KO) mice (n = 14 ).
(B) Plasma glucagon in fed control and KO mice
(n = 4–5).
(C) Representative blots of PEPCK, G6PC, and
calnexin in fed control and KO mice.
(D) Protein content of hepatic PEPCK and G6PC in
fed control and KO mice (n = 3–5).
(E) Plasma glucose in control and KO mice
following a 4-hr fast (n = 10–12).
(F) Plasma glucagon in control and KO mice
following a 4-hr fast (n = 4–5).
(G) Difference between 4 hr fasted and fed plasma
glucagon in control and KO mice (n = 4–5).
(H) Plasma ketone bodies in control and KO mice
following a 4-hr fast (n = 7–9).
All data are represented as mean ± SEM. Paired
t test with Tukey post hoc; *p < 0.05. ns, not
significant. See also Figure S1.reduces glucagon secretion from mouse islets in conditions of
hypoglycemia.
Cpt1a Knockout Reduces Fasting Plasma Glucose
To test whether FAO contributes to the counter-regulatory
response to hypoglycemia in vivo, we measured plasma
glucose and glucagon in aCPT1a-KOmice (Figure 3). Knockout
of Cpt1a did not change fed plasma glucose (p = 0.669; Fig-
ure 3A), glucagon (p = 0.608; Figure 3B), or hepatic protein con-
tent of the gluconeogenic enzymes phosphoenolpyruvate car-
boxykinase (PEPCK; p = 0.999) and glucose 6-phosphatase
(G6PC; p = 0.25; Figures 3C and 3D). Following a 4-hr fast,
plasma glucose was decreased in aCPT1a-KO mice compared
with control mice (p = 0.03; Figure 3E). Despite plasma glucose
being lower in aCPT1a-KO compared with control mice
following a 4-hr fast, plasma glucagon was no different between
the two genotypes (p = 0.987; Figure 3F). In line with previous
studies (Allister et al., 2013), 4 hr of fasting seemed to reduced
plasma glucagon in the fed state in both aCPT1a-KO and con-
trol mice. The change in plasma glucagon relative to the fed
state was greater in aCPT1a-KO compared with control mice
(p = 0.029; Figure 3G), indicating a change in the regulation of
circulating glucagon levels. We next tested whether ketone
body metabolism could contribute to the maintenance of
glucagon secretion in WT islets during hypoglycemia. Treating
WT islets with 3-hydroxybuterate (0.5 mM) reduced glucagon
secretion at 1 mM glucose (p = 0.0002; Figure S1J). This is in
agreement with studies from perfused rat pancreas and human
subjects (Ikeda et al., 1987; Quabbe et al., 1983) where(I) Glucagon secretion during perfusion in control (n = 3) and aCPT1a-KO (n = 3) mice at 4, 6, and 10 mM glu
(J) Average glucagon secretion from control (n = 3) and aCPT1a-KO mice (n = 3) at 4, 6, and 10 mM glucose, c
Two-way ANOVA with post hoc: #p < 0.05 versus control; *p < 0.05 versus 4 mM glucose.
Paired t test with Tukey post hoc or two-way ANOVA; *p < 0.05. See also Figure S1.
Cell Reglucagon secretion was decreased or
unaffected by ketones bodies. It is there-
fore unlikely that ketone metabolism in acells of the aCPT1a-KO mice could have compensated for the
reduced FAO. In support of this, the concentration of fasted
plasma ketone bodies was not different in aCPT1a-KO and
control mice (p = 0.21; Figure 3H). These data demonstrate
that FAO in a cells may contribute to maintaining blood
glucose during a 4-hr fast, and that this response is impaired
in aCPT1a-KO mice.
Disruption of FAO Changes Electrical Activity in a Cells
a cells are electrically active, utilizing these electrical signals to
drive glucagon secretion (Barg et al., 2000; Gromada et al.,
2007; MacDonald et al., 2007; Jacobson et al., 2009; Ramra-
cheya et al., 2010; Zhang et al., 2013; Gylfe and Gilon, 2014).
Given that inhibition of FAO decreased glucagon secretion (Fig-
ure 2), we hypothesized that this was due to an effect on a cell
membrane potential.
Inhibition of FAO resulted in a reduction in action potential
(AP) amplitude in mouse a cells (Figure 4). Etomoxir (100 mM)
reduced AP amplitude (p < 0.0001; Figures 4A–4D) and depolar-
ized the minimum membrane potential by 7 mV (p < 0.001; Fig-
ure 4E). Etomoxir also reduced the amplitude of intracellular
Ca2+ oscillations (Figure S2). The effect of pharmacological
blockade of FAO on membrane potential in a cells was mirrored
in aCPT1a-KO mice (Figures 4F–4M). a cells from aCPT1a-KO
mice had a lower AP amplitude compared with control mice
(p < 0.0001; Figure 4H). Minimal membrane potential in
aCPT1a-KO mice was depolarized compared with controls
(p = 0.026; Figure 4I). The frequency of AP firing was not
changed (p = 0.94; Figure 4J), suggesting that disruption ofcose.
alculated from the last 8–10 min in each condition.
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B Figure 4. Disruption of FFA Transport by
CPT1a Reduces Action Potential Amplitude
in Mouse a Cells
(A) Electrical activity in WT a cell at 1 mM glucose
with or without etomoxir (100 mM) (10 islets
from 6 mice).
(B) Average action potential waveform for (A), in
etomoxir compared with 1mMglucose, measured
over the entire experimental condition.
(C) Expanded view on 1 mM glucose and etomoxir
conditions for (A).
(D) Action potential amplitude in WT a cells at
1 mM glucose with or without etomoxir (100 mM)
(10 islets from 6 WT mice).
(E) Minimum membrane potential (VMIN) in WT a
cells at 1 mM glucose with or without etomoxir
(100 mM) (10 islets from 6 mice).
(F) Electrical activity in control a cell at 1 mM
glucose.
(G) Electrical activity in aCPT1a-KO a cell at 1 mM
glucose.
(H) Action potential amplitude in a cells from
aCPT1a-KO compared with control at 1 mM
glucose (8 control islets for 4 mice and 13
aCPT1a-KO islets for 4 mice).
(I) Minimal potential (VMIN) in a cells from
aCPT1a-KO mice compared with control at
1 mM glucose (8 control islets for 4 mice and 13
aCPT1a-KO islets for 4 mice).
(J) Firing frequency in control and aCPT1a-KO
islets at 1 mM glucose (8 control islets for 4 mice)
and 13 aCPT1a-KO islets for 4 mice).
(K) Action potential amplitude in a cells from con-
trol and aCPT1a-KO islets at 1 and 10mMglucose
(6 control islets for 4 mice and 6 aCPT1a-KO islets
for 4 mice).
(L) Action potential amplitude in a cells from
aCPT1a-KO islets at 1 mM glucose with or without
etomoxir (100 mM) (3 islets from 3 mice for each
genotype).
(M) Raster plots demonstrating robust action
potentials in 5 control a cells, and weaker action
potentials in 5 a cells from aCPT1a-KO islets.
Paired t test with Tukey post hoc; *p < 0.05; **p <
0.01; ***p < 0.001. See also Figures S1 and S2.FAO reduces glucagon secretion by reducing AP amplitude,
rather than firing frequency. High glucose (>6 mM) is known to
decrease glucagon secretion by reducing AP amplitude in a
cells by 17 mV (Zhang et al., 2013). Consistent with this, in
control mice, high glucose (10 mM) decreased AP amplitude
by 12 ± 2 mV compared with 1 mM glucose (p = 0.014;
Figure 4K). In contrast, 10 mM glucose did not decrease AP
amplitude in aCPT1a-KO mice (p = 0.94). Furthermore, the
reduction in AP amplitude in aCPT1a-KO at 1 mM glucose
was significantly greater than in control islets due to 10 mM
glucose (p = 0.005). Therefore, the suppression of AP amplitude
by FAO disruption is physiologically significant.
Disruption of FAOAlters aCell Membrane Potential via a
KATP-Independent Mechanism
We investigated whether the effect of CPT1 inhibition was due to
a decrease in KATP channel conductance (GKATP). First, we noted3304 Cell Reports 23, 3300–3311, June 12, 2018that our pharmacological data (Figure 4) appeared incompatible
with a KATP-dependent mechanism because etomoxir
decreased intracellular ATP ([ATP]i) (Figure 1B), which would
result in an increase in GKATP, consequently hyperpolarizing
the membrane. Nevertheless, because the KATP channel is
crucial to glucagon secretion (MacDonald et al., 2007; Zhang
et al., 2013), we wanted to investigate the dependence (if any)
of the effect on KATP channel activity.
We measured GKATP in response to inhibition of CPT1a (Fig-
ure 5). Unexpectedly, inhibition of CPT1a with etomoxir (Fig-
ure 5A; p = 0.73; 100 mM) or by gene knockout (Figure 5C;
p = 0.85) did not change GKATP in a cells. Because b cells
have a larger GKATP (Briant et al., 2017), we used them to
further interrogate any pharmacological effects of etomoxir on
GKATP (Figures 5E–5H). Etomoxir did not change GKATP in b
cells at low glucose (p = 0.96). We mimicked the effects of
etomoxir on [ATP]i by artificially decreasing [ATP]i. To this
Figure 5. Inhibition of CPT1a Disrupts a Cell Membrane Potential via a KATP-Independent Mechanism
(A) GKATP in wild-type (WT) mouse a cells at 1 mM glucose with or without etomoxir (100 mM) (6 islets, 5 mice).
(B) Holding current in WT mouse a cells at 1 mM glucose with or without etomoxir (100 mM) (11 islets, 6 mice).
(C) GKATP in a cells from aCPT1a-KO mice compared with control at 1 mM glucose (8 control islets from 4 mice and 13 aCPT1a-KO islets from 4 mice).
(D) Holding current in a cells from aCPT1a-KO mice compared with control at 1 mM glucose (8 control islets for 4 mice and 13 aCPT1a-KO islets
for 4 mice).
(E) Electrical activity in WT b cell at 1 mM glucose with or without etomoxir (100 mM) and at 20 mM glucose.
(F) GKATP in WT b cell at 1 mM glucose with or without etomoxir (100 mM) and at 20 mM glucose.
(G) Grouped data of VM recording in b cells following etomoxir and 20 mM glucose application (6 islets from 6 WT mice).
(H) Grouped data of GKATP recording in b cells following etomoxir and 20 mM glucose application (6 islets from 6 WT mice).
(I) To mimic the effects of etomoxir in 1 mM glucose on [ATP]i, we artificially reduced [ATP]i by setting the pipette concentration (1 mM) to be lower than
the putative [ATP]i in 1 mM glucose (>1 mM; Detimary et al., 1998) and measured GKATP. The arrow denotes when whole cell was achieved, which initiates the
run-down of [ATP]i from the endogenous concentration to the pipette concentration.
(J) Holding current (Ihold) from (I).
(K) GKATP and Ihold after 0, 1, and 3 min of whole-cell recording (I).
(L) Grouped data, recording GKATP during artificial run-down of [ATP]i (4 WT islets, 4 mice).
(M) Grouped data, recording Ihold during artificial run-down of [ATP]i (4 WT islets, 4 mice).
(N) Membrane potential recording from a WT a cell. Tolbutamide was applied to maximally open KATP channels. A negative current was then injected to
hyperpolarize the a cell. Etomoxir was still able to depolarize a cells.
(O) Grouped data for change in minimum potential (VMIN) (n = 8 islets, n = 4 mice).
(P) Grouped data for change in action potential amplitude (n = 8 islets, n = 4 mice).
Paired t test with Tukey post hoc or two-way ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001. See also Figures S1 and S2.end, we continuously monitored GKATP in standard whole cell
while diluting the cell interior with a pipette solution containing
1 mM ATP (Figures 5I–5M). This would achieve a bona fide
decrease in [ATP]i because the ATP concentration in a cells
at 1 mM glucose is >1 mM (Detimary et al., 1998). Decreasing
[ATP]i in this way did not change GKATP in a cells (p = 0.93; Fig-
ures 5I and 5L), consistent with what has been shown in b cells
(Tarasov et al., 2006). In a final set of experiments, we
applied etomoxir in the presence of the KATP channel inhibitor
tolbutamide (100 mM; Figure 5N). In these experiments, when
the a cells were repolarized by injection of negative currents,etomoxir was still able to depolarize the membrane potential
(p = 0.001; Figure 5O) and reduce AP amplitude (p = 0.042; Fig-
ure 5P). This effect of etomoxir must be independent of KATP
channel closure. In conclusion, blockade of FAO via inhibition
of CPT1 depolarizes the a cell membrane potential by a KATP
channel-independent mechanism.
We therefore sought an ATP-dependent mechanism that
could explain these data: namely, result in a depolarization of
membrane potential, following a decrease in [ATP]i. It can be
seen that there was an increase in the holding current (the
current required to hold the membrane potential at 70 mV)Cell Reports 23, 3300–3311, June 12, 2018 3305
Figure 6. FFA Oxidation Maintains a Cell
Membrane Potential by Energizing the
Na+-K+ Pump
(A) Electrical activity in a WT a cell in response to
1 mM glucose with or without ouabain (0.5 mM).
(B) Average action potential waveform for (A)
during 1 mM glucose and ouabain, measured over
entire experimental condition.
(C) Expanded view on 1 mM glucose and ouabain
conditions for (A).
(D) Grouped data for change in action potential
amplitude in response to 1 mM glucose with or
without ouabain (0.5 mM; 7 islets, 4 WT mice).
(E) Grouped data for change in minimum mem-
brane potential (VMIN) in WT a cells in response to
1 mM glucose with or without ouabain (0.5 mM;
7 islets, 4 WT mice).
(F) The holding current in absolute value in WT a
cells, in response to 1 mM glucose with or without
ouabain (0.5 mM; 7 islets, 4 WT mice).
(G) Glucagon secretion from WT islets at 1 and
10 mM glucose with or without ouabain (0.5 mM;
n = 4 mice).
(H) Mathematical model of a cell electrical activity
demonstrates that a reduction of Na+-K+ pump
activity (Ipump) reduces action potential amplitude,
mimicking blockade of CPT1a.
(I) Accompanying model of glucagon secretion
demonstrates that this results in a reduction of
glucagon secretion, also mimicking blockade of
CPT1a.
All data are represented as mean ± SEM. Paired
t test with Tukey post hoc or two-way ANOVA
with Student-Newman-Keuls post hoc; *p < 0.05.
See also Figure S1.following pharmacological inhibition of CTP1 (p = 0.008; Fig-
ure 5B), knockout ofCpt1a (p = 0.017; Figure 5D), or by artificially
reducing [ATP]i in 1 mM glucose (Figures 5J–5M; p = 0.049).
FFA Oxidation Maintains a Cell Membrane Potential and
Glucagon Secretion by Energizing the Na+-K+ Pump
The Na+-K+ pump is an ATPase, extruding intracellular Na+ in ex-
change for K+. Its operation is electrogenic and generates an
outward current. Thus, reduced activity of the Na+-K+ pump
would account for the increase in holding current following inhi-
bition of CPT1a (Figures 5B and 5D). We therefore postulated
that membrane potential and AP amplitude are maintained in
low (1 mM) glucose because FAO energizes the Na+-K+ pump.
To investigate this, we exposed islets fromWTmice to 0.5 mM
ouabain in 1 mM glucose (Figure 6). Blockade of Na+-K+ pump
activity decreased AP amplitude (p = 0.0005; Figures 6A–6D).
Ouabain also reduced glucagon secretion in low glucose
(p = 0.0015; Figure 6G), but did not change GKATP in a cells (Fig-
ures S1D and S1E) or b cells (p = 0.45; Figures S1F and S1G).
Thus, this depolarization was not due to a reduction in GKATP.
Ouabain did, however, increase themagnitude of the holding cur-
rent in both a cells (p = 0.0132; Figure 6F) and b cells (p = 0.0242;
Figure S1H). Therefore, all of the effects of FAO inhibition on elec-3306 Cell Reports 23, 3300–3311, June 12, 2018trical activity (Figures 4 and 5) were mirrored by blockade of the
Na+-K+ pump with ouabain. Together, these data suggest that
Na+-K+ pump activity is high in low glucose, and preservation
of this activity by FAO maintains a hyperpolarized membrane
potential, and therefore AP amplitude and glucagon secretion,
in a cells. To test the consistency of our experimental observa-
tions with this theory, we constructed a mathematical model of
membrane potential in a cells (Figures 6H and 6I). Reducing
energy supply to the Na+-K+ pump from FAO in the model reca-
pitulated the experimental data, supporting our hypothesis.
Reduced FAO in Human Islets Causes a Reduction in
Electrical Activity and Glucagon Secretion
Islets from human donors stained positive for CPT1a, with
co-localization (90%) of glucagon and CPT1a (Figure 7A). Inhi-
bition of FAO with etomoxir (100 mM) suppressed glucagon
secretion at 1mMglucose (p = 0.008; Figure 7B). Finally, analysis
of membrane potential in a cells revealed that etomoxir reduces
AP amplitude (p = 0.034; Figures 7C–7E) and depolarizes the
membrane (p = 0.035; Figure 7F). These observations recapitu-
late our findings in mouse islets and suggest that FAO in human
a cells contributes to the maintenance of membrane potential
and glucagon secretion in low glucose conditions.
A B
C
D
E F
Figure 7. CPT1a Blockade in Human Islets
Reduces a Cell Membrane Potential and
Glucagon Secretion
(A) Immunofluorescent detection of glucagon (red)
and CPT1a (green) in isolated human islets (scale
bar, 50 mm).
(B) Glucagon secretion from human islets at 1 and
10 mM glucose with or without etomoxir (100 mM)
reduced glucagon secretion (n = 3 donors).
(C) Electrical activity in human a cells at 1 mM
glucose with or without etomoxir (100 mM) (n = 3
donors,%7 cells).
(D) Expanded view of 1 mM glucose and etomoxir
conditions for (C).
(E) Action potential amplitude in human a cells at
1 mM glucose with or without etomoxir (100 mM)
and at 10 mM glucose (n = 3 donors,%7 cells).
(F) Minimum potential in human a cells at 1 mM
glucose with or without etomoxir (100 mM) and at
10 mM glucose (n = 3 donors,%7 cells).
All data are represented as mean ± SEM. Paired
t test with Tukey post hoc or two-way ANOVA
with Student-Newman-Keuls post hoc; *p < 0.05.DISCUSSION
In this study we investigated the role of FAO in regulating
glucagon secretion under hypoglycemic conditions. We found
that pharmacological blockade or knockout of CPT1a pro-
foundly reduced glucagon secretion from mouse islets at low
glucose. These findings were mirrored in human islets with
pharmacological inhibition of CPT1. In both mouse and human
a cells, inhibition of CPT1was associated withmembrane poten-
tial depolarization and reduced AP amplitude.
Our findings suggest that during fasting, when blood glucose
becomes low, fatty acids play a significant role in maintaining
blood glucose by sustaining basal glucagon secretion. We
show that FAO contributes to ATP production in low glucoseCell Reconditions in a cells, and that this FFA-
derived ATP maintains glucagon secre-
tion by energizing the Na+-K+ pump. We
propose that in low glucose concentra-
tions, ATP generated by FAO is an essen-
tial energy supply for the Na+-K+ pump,
keeping the a cell membrane sufficiently
repolarized to prevent voltage-depen-
dent inactivation of the ion channels
involved in AP firing, thus allowing the
generation of large-amplitude APs.
When glucose becomes available, ATP
derived from glucose oxidation triggers
membrane depolarization by closure of
KATP channels, leading to a KATP-depen-
dent reduction in glucagon secretion.
The KATP channel has been demon-
strated to mediate the intrinsic regula-
tion of glucagon secretion from a cells
(MacDonald et al., 2007; Zhang et al.,
2013). According to this model ofcounter-regulation, a reduction in glucose concentrations
causes opening of KATP channels, a hyperpolarization of
membrane potential, an increase in AP amplitude, and, there-
fore, glucagon secretion. However, this model is not wholly
accepted (see Gylfe, 2013, 2016; Gylfe and Gilon, 2014). In
low glucose, we observed that inhibition or reduction of
FAO depolarized a cells and decreased glucagon secretion.
If this depolarizing effect of inhibiting FAO were mediated
by changes in KATP channel activity, we would expect to
observe a reduction in KATP conductance. However, this is
incompatible with our data because inhibition of FAO
decreases [ATP]i, which would cause an increase in KATP
conductance. Furthermore, we did not observe a change in
KATP conductance in response to CPT1a inhibition, eitherports 23, 3300–3311, June 12, 2018 3307
pharmacologically or via knockout, suggesting that KATP
channels are not directly involved.
To identify a possible mechanism underlying the effect on
a cell electrical activity, we considered energy-consuming
cellular mechanisms that result in membrane depolarization
following a reduction in cellular ATP. The Na+-K+ pump is amajor
energy consumer in most types of cells (10% in muscle
(Pirkmajer and Chibalin, 2016), 40% in neurons (Attwell and
Laughlin, 2001), and 50% in the kidney (Clausen et al., 1991),
utilizing more ATP than any other enzyme and consuming
19%–28% of whole-body ATP (Rolfe and Brown, 1997). The a
cell appears to be no exception; we show that the application
of the Na+-K+ pump inhibitor ouabain robustly depolarizes a
cells. Considering that the Na+-K+ pump has a Km of 0.4 mM
for ATP (Javorkova´ et al., 2009), a cell pump activity at 1 mM
glucose would be drastically decreased when ATP levels are
further reduced. Furthermore, this Km is 30 times higher than
the Km of the KATP channel to ATP (Tarasov et al., 2006; Javor-
kova´ et al., 2009). The pump would therefore turn off before
the channel would be affected by the reduction in [ATP]i. We
suggest that the reduction in ATP, which occurs when FAO is
blocked with etomoxir or when Cpt1a is knocked out in a cells,
leads to a reduction in Na+-K+ pump activity in low glucose.
Defects in mitochondrial b-oxidation have serious clinical
consequences (Kompare andRizzo, 2008) and account for ama-
jor cause of hypoglycemic seizures. There are at least 12 FAO
disorders described, of which 10 are associated with routine
fasting hypoglycemia (Grosse et al., 2006). CPT1a deficiency
presents in infancy, is characterized by hypoketotic hypoglyce-
mia (Ogier de Baulny et al., 1995; Greenberg et al., 2009), and
is treated with frequent feedings to prevent prolonged fasting
(Longo et al., 2006).
It has previously been suggested that the liver uses ATP
generated from FAO to maintain glucose production (Staehr
et al., 2003; Lam et al., 2003). However, recent findings suggest
that hepatic FAO is expendable for maintaining 24-hr fasting
blood glucose (Lee et al., 2016). Thus, loss of CPT1a activity in
the liver of CPT1a-deficient patients may cause the hypoketone-
mia, but not the hypoglycemia. Our data support this and
indicate that the hypoglycemia in these patients may be caused
by a loss of FAO in the a cell and, consequently, reduced
glucagon secretion.
EXPERIMENTAL PROCEDURES
All animal experiments were conducted in accordance with the UK Animals
Scientific Procedures Act (1986) and University of Oxford ethical guidelines,
and were approved by the local Ethical Committees. Human pancreatic islets
were isolated (with ethical approval and clinical consent) at the Diabetes
Research and Wellness Foundation Human Islet Isolation Facility (OCDEM,
Oxford, UK) from pancreases of six non-diabetic donors. Donors were on
average 61 years old (range 25–76) with a BMI of 24 (range 19.3–30) and
HbA1c of 5.5% (range 5.3–5.9). Three of six donors were female.
Animals and Generation of aCPT1a-KO Mice
C57BL/6j mice were used as WT mice in this study. To generate aCPT1a-KO,
mice carrying a loxP insert flanking exons 11 and 12 of the Cpt1a gene
(Schoors et al., 2015) were crossed with mice carrying Cre recombinase under
the control of the proglucagon promoter (Parker et al., 2012). Mice homozy-
gous for the loxP allele were used as controls and are referred to as such.3308 Cell Reports 23, 3300–3311, June 12, 2018In Vivo Measurements of Plasma Glucose, Glucagon, and Ketone
Body Concentration
Plasma glucose, glucagon, and ketone body measurements were conducted
in vivo on aCPT1a-KO and control mice in response to fasting. Mice were
restrained, and a tail-vein sample of plasma was used to measure fed
plasma glucose and ketone bodies. Mice were then individually caged for
the 4-hr fasting period and given unrestricted access to water during this
time. At the end of the fasting period, mice were restrained and a tail-vein
sample of plasma was used to measure plasma glucose and ketone bodies.
Mice were then culled by cervical dislocation and trunk plasma collected.
The serum was then removed and stored at 80C. Serum samples were
used to measure plasma glucagon. Measurements were conducted using
a dual mouse insulin/glucagon assay system (Meso Scale Discovery, MD,
USA), according to the manufacturer’s protocol.
Isolation of Pancreatic Islets
Mice at 12–16 weeks of age were killed by cervical dislocation (Schedule 1
procedure). Pancreatic islets were isolated by Liberase digestion followed
by manual picking. Islets were used acutely and were, pending the experi-
ments, maintained in tissue culture for <24 hr in RPMI 1640 (11879-020;
GIBCO, Thermo Fisher Scientific) containing 1% penicillin/streptomycin
(1214-122; GIBCO, Thermo Fisher Scientific), 10% fetal bovine serum
(FBS; F7524-500G; Sigma-Aldrich), and 7.5 mM glucose before the
measurements.
Hormone Release Measurements
Measurements of insulin and glucagon secretion were performed using
sequential incubations of isolated mouse and human islets as described in
the Supplemental Information.
Electrophysiology
All electrophysiological measurements were performed at 33C to 34C on a
cells within intact islets (from aCPT1a-KO mice, littermate controls, WT
C57BL/6j mice, and human islets). Membrane potential and whole-cell
KATP-current recordings were conducted using the perforated patch tech-
nique, as previously described (De Marinis et al., 2010). The composition of
solutions is described in the Supplemental Information.
ATP Imaging
The ATP/ADP sensor Perceval was used, as previously described (Adam
et al., 2017).
FFA Oxidation Measurements
aTC1-6 cells were cultured overnight in RPMI culturemedium containing 5mM
glucose. On the day of the experiment, the cells were incubated in 0 mM
glucose Krebs Ringer buffer (KRB) with or without etomoxir. The cells were
then exposed to 0.3 mM palmitate containing 0.22 MBq [3H]palmitate for
1 hr. The supernatant was then subjected to a Falkes extraction and the
aqueous phase assayed for H3 content. From this, b-oxidation was calculated
and normalized to cell count. Further details are in the Supplemental
Information.
Mathematical Model of a Cell Membrane Potential
Amathematical model of Na+-K+ pump activity was added to a model of a cell
membrane potential (Briant et al., 2018) and simulated in the simulation envi-
ronment NEURONwith a 25-mS time step. Themodel is further described in the
Supplemental Information.
Statistical Tests
All data are reported as mean ± SEM, unless otherwise stated. Statistical
significance was defined as p < 0.05. All statistical tests were conducted
in Prism (GraphPad Software, San Diego, CA, USA). For two groupings, a
t test was conducted with the appropriate post hoc test. For more than
two groupings, a one-way ANOVA was conducted. If there were two inde-
pendent variables, a two-way ANOVA was conducted. If the data passed
normality criteria (D’Agostino’s test of normality and Bartlett’s test of equal
variances), a parametric test was conducted with the appropriate post hoc
test (Tukey or Student-Neumann-Keuls). If the normality criteria were not
met, a Kruskal-Wallis test with Dunn’s multiple comparison test was
conducted.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.05.035.
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 Supplementary Figure 1 (Related to Figure 1-3) 
(A) Insulin secretion from WT islets at 1 and 10mM glucose with or without etomoxir (100 
μM) reduced glucagon secretion (n=3).  
(B) Insulin secretion from control and αCPT1a-KO mice at 1 and 10mM glucose (n=6).  
(C) Insulin content from control and αCPT1a-KO islets (n=6). 
(D) Continuously recording GKATP in WT α-cells at 1mM glucose following ouabain 
(0.5mM) application.  
(E) GKATP in a WT α-cell at 1mM glucose with or without ouabain (0.5mM). 
(F) Continuously recording GKATP in a WT β-cell at 1mM glucose following ouabain 
(0.5mM) application 
(G) GKATP in a WT β-cell at 1mM glucose with or without ouabain  
(I) Grouped GKATP data from WT α-cell at 1mM glucose with or without ouabain (0.5mM) (3 
cells from 3 mice). 
(J) Glucagon secretion in WT mouse islets at 1 or 10mM glucose with or without 3-
hydroxybuterate (0.5mM) (n=3). 
All data are represented as mean ± SEM. Paired t-test with Tukey post-hoc or two-way 
ANOVA with Student Newman-Keuls post-hoc; * = p<0.05. 
  
 Supplementary Figure 2 (Related to Figure 4) 
 
(A) Fluorescence intensity of intracellular calcium ([Ca2+]i) measured using Fluo-4 from 
intact pancreatic WT islets. Recordings were conducted in 3 mM glucose and 3 mM glucose 
with 100 µM etomoxir. 
(B) For each experimental condition, the peak of each [Ca2+]i spike was marked and a peak-
triggered average waveform of [Ca2+]i computed. The amplitude (Amp) of this average 
waveform was then measured. 
(C) Amplitude of average [Ca2+]i spike waveform (Amp) in 3 mM glucose with or without 
100 µM etomoxir. (4 islets, 4 mice) 
(D) Frequency of [Ca2+]i spikes in 3 mM glucose with or without 100 µM etomoxir. (4 islets, 
4 mice) 
All data are represented as mean ± SEM. Paired t-test with Tukey post-hoc; ** = p<0.01. 
Supplementary methods 
Ethics 
All animal experiments were conducted in accordance with the UK Animals Scientific Procedures Act (1986) 
and University of Oxford ethical guidelines, and were approved by the local Ethical Committees. Human 
pancreatic islets were isolated, with ethical approval and clinical consent, at the Diabetes Research and Wellness 
Foundation Human Islet Isolation Facility (OCDEM, Oxford, UK).  
Animals  
All animals were kept in a specific pathogen-free (SPF) facility under a 12:12 hour light:dark cycle at 22 °C, 
with unrestricted access to standard rodent chow and water. C57BL/6j mice used in this study are referred to as 
wild-type (WT) mice. To generate α-cell specific Cpt1a knockout mice (αCPT1a-KO), mice carrying a loxP 
insert flanking exons 11 and 12 of the Cpt1a gene (Schoors et al., 2015) were crossed with mice carrying a Cre 
recombinase under the control of the proglucagon promoter (Parker et al., 2012). Mice homozygous for the loxP 
allele were used as controls, and are referred to as such.  
In vivo measurements of plasma glucose, glucagon and ketone body concentration 
Plasma glucose, glucagon and ketone body measurements were conducted in vivo on αCPT1a-KO and control 
mice in response to fasting. Experiments followed a strict time schedule to minimise experimental variation. 
Plasma glucose was measured with an Accu-Chek Aviva (Roche Diagnostic, UK) and plasma ketone bodies 
with a FreeStyle Libre system (Abbott Laboratories Ltd, Maidenhead, UK). Bovine aprotinin 2µl (4 TIU/ml) 
(Sigma-Aldrich, UK) was added to all plasma samples. 
Fed plasma glucose: Mice were restrained and a tail vein sample of blood was used to measure fed plasma 
glucose and ketone bodies. At this stage, some mice were culled, and the liver was removed, snap frozen in 
liquid nitrogen and stored at -80 °C. Other mice were not culled, but instead used for subsequent in vivo studies. 
Fasting studies: Mice were restrained and fed plasma glucose was measured as above. Mice were then 
individually caged for the 4 hour fasting period (8.30am-12.30pm) and given unrestricted access to water during 
this time. At the end of the fasting period, mice were restrained and a tail vein sample of plasma was used to 
measure plasma glucose and ketone bodies. Mice were then culled by cervical dislocation and trunk plasma 
collected in EDTA coated tubes. Blood sampels were kept on ice and imediately centrifuged at 2700 rpm for 10 
min to obtain plasma. The plasma was then removed and stored at -80 °C. 
Plasma glucagon measurements: Plasma samples (stored at -80 °C prior) were used to measure plasma 
glucagon. Measurements were conducted using a mouse glucagon assay system (Mercodia, Upsala, Sweden), 
according to the manufacturers protocol. 
 
Pharmacological blockade of CPT1 
 
Pharmacological blockade of CPT1 was achieved using the CPT1 inhibitor etomoxir (Sigma-Aldrich, UK). 
Concentrations of 25-200 µM have been used to block CPT1 activity in islet cells in other studies (Chen et al., 
1994, Lehtihet et al., 2003). Prolonged exposure to high concentrations (1 mM) of etomoxir is known to 
increase ROS, deplete ATP and lead to cell death (Pike et al., 2011). Although our application of etomoxir was 
short (<1 hour), we opted for 100 µM to avoid this. This concentration of 100 µM was used throughout this 
study. 
 
Isolation of pancreatic islets 
Mice at 12-16 weeks of age were killed by cervical dislocation (Schedule 1 procedure). Pancreatic islets were 
isolated by liberase digestion followed by manual picking. Islets were used acutely and were, pending the 
experiments, maintained in tissue culture for <24 hour in RPMI 1640 (11879-020, Gibco, Thermo Fisher 
Scientific) containing 1% pennicillin/streptomycin (1214-122, Gibco, Thermo Fisher Scientific), 10%FBS 
(F7524-500G, Sigma-Aldrich) and 7.5mM glucose prior to the measurements. 
Cell culture experiments  
The αTC1-clone 6 cell line (αTC1-6; CRL-2934, ATCC), was cultured in RPMI 1640 (118279-020, Gibco, 
Thermo Fisher Scientific) containing 15mM Hepes (15630-56, Gibco, Thermo Fisher Scientific), 1% 
penicillin/streptomycin (15140-122, Gibco, Thermo Fisher Scientific), 10%FBS (10270-10, Gibco, Thermo 
Fisher Scientific) and 15mM glucose. For all experiments, cells were plated in 12 or 6 well plates, and, after 3 
days of culture, glucose concentration was lowered to 5 mM over night and experiments were performed the 
next day. For knock down of Cpt1a,  αTC1-6 cells were cultured for 2 days in standard medium and then 
transfected with scrambled control siRNA (SR30004,Origene) or siRNA specifically targeting Cpt1a mRNA (J-
042456-10-0002, Dharmacon Inc.). After 36 hour, medium was changed to culture medium containing 5 mM 
glucose and experiments were performed the next day. The efficiency of downregulation was assessed by 
Western blot. 
 
Evaluation of protein expression 
For evaluation of protein expression, αTC1-6 cells were lysed in Hepes KOH pH7.6 buffer containing 0.1% 
TritonX-100 (Sigma-Aldrich) and protease and phosphatase inhibitors (Roche, UK). Lysates were immedaitely 
sonicated and then stored at -80°C for further analysis. Protein content was determined by bicinchoninic acid 
assay (Thermo Fisher Scientific, UK).   
 
Patch-clamp electrophysiology in islets 
Mouse and human islets were used for patch-clamp electrophysiological recordings. These recordings (in intact 
islets) were performed at 33-34 ⁰C using an EPC-10 patch-clamp amplifier and PatchMaster software (HEKA 
Electronics, Lambrecht/Pfalz, Germany). Currents were filtered at 2.9 kHz and digitized at > 10 kHz. A new 
islet was used for each recording. Membrane potential (𝑉𝑀) recordings were conducted using the perforated 
patch-clamp technique, as previously described (De Marinis et al., 2010, Zhang et al., 2013). The pipette 
solution contained (in mM) 76 K2SO4, 10 NaCl, 10 KCl, 1 MgCl2·6H20 and 5 Hepes (pH 7.35 with KOH). For 
these experiments, the bath solution contained (mM) 140 NaCl, 3.6 KCl, 10 Hepes, 0.5 MgCl2·6H20, 0.5 
Na2H2PO4, 5 NaHCO3 and 1.5 CaCl2 (pH 7.4 with NaOH). Amphotericin B (final concentration of 25mg/mL, 
Sigma-Aldrich) was added to the pipette solution to give electrical access to the cells (series resistance of <100 
MΩ). α-cells were confirmed by their activity at 1 mM glucose and a logistic regression model that can identify 
cell type with 94% accuracy (Briant et al., 2017). Recordings were made during brief (5-10 min) exposure to 
etomoxir (100 µM), and action potential morphology was quantified and compared. 
 
The morphology of action potentials and frequency of firing was calculated in MATLAB v. 6.1 (2000; The 
MathWorks, Natick, MA). In brief, a peak-find algorithm was used to detect action potentials. This was then 
used to calculate firing frequency in different experimental conditions. The peaks were then used as triggers to 
create a waveform-triggered average of membrane potential in different experimental conditions. The window 
chosen for this analysis was the entire experimental condition. This average action potential waveform was 
generated over a symmetric 50 ms window (25 ms before and after the trigger). The minimal membrane 
potential (VMIN) was defined as the minimal membrane potential preceeding the action potential in this window. 
The action potential amplitude was defined as the amplitude of this average waveform. Analysis of action 
potential morphology in αCPT1a-KO and control mice was conducted ’blind’ to mouse strain (blinding was 
conducted by an acknowledged independent researcher). 
 
Quantitive imaging of ATP in islets 
Time-lapse imaging of the ATP/ADP ratio in WT mouse islets was performed using 14× magnification on a 
Zeiss AxioZoom V16 microscope, as previously described (Adam et al., 2017). In brief, islets were transduced 
with an adenovirus delivering Perceval, a recombinant sensor of ATP/ADP. Groups of islets were imaged 
simultaneously 24 hour post-transduction at glucose concentrations as indicated, with single-cell resolution. 
Time-lapse images were collected every 30 s, and the bath solution was perifused at 60 μl/min at 34 °C. The 
bath solution was as described for patch-clamp electrophysiology. 
 
Ca2+ imaging in islets 
Time-lapse imaging of the intracellular Ca2+ concentration ([Ca2+]i) in WT mouse islets was performed on the 
inverted Zeiss AxioVert 200 microscope, equipped with the Zeiss LSM 510-META laser confocal scanning 
system, using a 40x/1.3 NA objective. Mouse islets were loaded with 6 mM of the Ca2+-sensitive dye Fluo-4 for 
90 min before being transfered to a recording chamber. Mice were then continuously perfused with bath solution 
(same solution as described for patch-clamp electrophysiology, above) at a rate of 200 µL/min. Fluo-4 was 
excited at 488 nm and fluorscence emission collected at 530 nm. The pinhole diameter was kept constant, and 
frames of 256x256 pixels were taken every 1-3 s. α-cells were identified by the presence of oscillations in 
[Ca2+]i in low (3 mM) glucose and an excitatory response to glutamate. 
 
Hormone secretion measurements 
Islets: Islets isolated from WT, αCPT1a-KO and control mice were incubated for 1h in RPMI supplemented 
with 7.5 mM glucose in a cell culture incubator. Size-matched batches of 20 islets were pre-incubated in 0.2 ml 
KRB with 2mg/ml BSA (S6003, Sigma-Aldrich) and 3 mM glucose for 1 hour in a water-bath at 37 ⁰C. 
Following this islets were sequentially subjected to 0.2 ml KRB with 2 mg/ml BSA with 1 mM or 10 mM 
glucose for 1 hour. For Ketone body experiments islets were subjected to with 1 mM or 10 mM glucose with or 
without 0.5mM 3-hydroxybuterate for 1 hour  After each incubation, the supernatant was removed, quickly 
frozen and stored at -80 ⁰C. At the end of the experiment the islets were lysed in 0.1 ml of HCl:ethanol (1:15) 
and samples were sonicated and stored at -80 ⁰C. 
αTC1-6 cells: on the day of the experiment, cells were pre-incubated for 1 hour at 0 mM glucose KRB, with or 
without etomoxir (100 μM). The cells were then incubated for 1 hour in KRB containing either 1 or 10 mM 
glucose. After 1 hour, the supernatant was removed and centrifuged at 800 g, 4 °C for 10 min, to remove dead 
cell debris. The supernatant was transferred to clean eppendorf tubes and stored at -80 °C. Cells in the plate 
were lysed with 0.5 ml of HCl:ethanol (1:15), sonicated and stored at -80°C. Glucagon and insulin from 
secretion and content samples were measured using MSD mouse insulin/glucagon duplex sandwich ELISA 
(Mesoscale Discovery, USA), according to the manufacturers protocol. 
 
Pancreas perfusion: Measurements of glucagon secretion  was performed using in situ pancreatic perfusion. 
Briefly, the aorta was ligated above the coeliac artery and below the superior mesenteric artery and then 
cannulated. The pancreas was perfused with KRB containing varying concentrations of glucose in the following 
order 4, 6 and then 10 mM glucose at a speed of 0.240 ml/min using an Ismatec Reglo Digital MS2/12 
peristaltic pump. The perfusate was maintained at 37°C using a Warner Instruments temperature control unit 
TC-32 4B in conjunction with a tube heater (Warner Instruments P/N 64-0102) and a Harvard Apparatus heated 
rodent operating table. The effluent was collected in intervals of 2 min in to 96 well plate on ice containing 
aprotenin. Samples were subsequently stored at -80°C.  Glucagon content in perfusate were measured using 
mouse glucagon RIA (Euro-diagnostica, Sweden), according to the manufacturers protocol. 
 
FFA oxidation measurements    
αTC1-6 cells were cultured over night in RPMI culture medium containing 5 mM glucose. On the day of the 
experiment, the cells were incubated in KRB with 0 mM glucose and the relevant treatment (e.g. etomoxir). The 
cells were then exposed to 0.3 mM palmitate containing 0.22Mbeq H3palmitate for 1 hour. The supernatant was 
then subjected to a Falkes extraction and the aquaeus phase assayed for H3 content. From this, β-oxidation was 
calculated and normalised to cell count.  
 
Immunohistochemistry and immunoblotting 
Mouse or human pancreata  or islets were fixed in 0.4% PFA 10% neutral-buffered formalin, dehydrated and 
processed for paraffin wax embedding and sectioning (3µm).   
 
Immunostaining was performed using antibodies to CPT1a (ab128568, ABCAM, Cambridge, UK), CPT1b 
(ABCAM, Cambridge, UK), glucagon (ABCAM, Cambridge, UK) or glucagon (Sigma-Aldrich).  CPT1b and 
glucagon staining was visualised using anti rabbit Alexafluor 488 (Molecular Probes, Thermo Fisher Scientific) 
or anti rabbit FITC secendary antibody. CPT1a staining was enhaced using VectaFluor™ Excel Amplified 
DyLight® 594 Anti-Mouse IgG Kit (DK-2594, Vectorlabs). Images were acquired with a Zeiss LSM510 META 
confocal imaging system. 
 
For immunoblotting, cell lysates were diluted to a concentration of 1µg/ml in 2x Sample Buffer (BioRad) with β-
mercaptoethanol (Sigma-Aldrich). After addition of the Laemmli sample buffer the proteins were separated usign 
SDS-PAGE, transferred to a PVDF membranes and visualised using antibodies to CPT1a, G6PC, β-actin (AbCam, 
UK), PEPCK (Cayman Chemical), calnexin (Millipore Merk) and HRP-conjugated secondary antibodies (Thermo 
Fisher Scientific, Rugby, UK). Blots were developed using ECL detection reagent (BioRad), images acquired on 
a ChemiDoc imager (Bio-Rad) and analysed using ImageLab software (BioRad). All data were normalised to 
either calnexin or β-actin and expressed as fold change of control.  
 
Mathematical model of α-cell membrane potential 
All simulations were conducted in the simulation environment NEURON using CVODE and a 25 μs timestep 
(Carnevale and Hines, 2006). The equation describing membrane potential (𝑉𝑀) in the α-cell model is: 
 𝐶𝑐𝑒𝑙𝑙
𝑑𝑉𝑀
𝑑𝑡
= −(𝐼𝐶𝑎𝐿 + 𝐼𝐶𝑎𝑁 + 𝐼𝐶𝑎𝑇 + 𝐼𝑁𝑎 + 𝐼𝐾 + 𝐼𝐾𝐴𝑇𝑃 + 𝐼𝐾𝐴 + 𝐼𝐿) (1) 
where: 𝐶𝑐𝑒𝑙𝑙  is the cell capacitance; 𝐼𝐶𝑎𝐿 , 𝐼𝐶𝑎𝑁 and 𝐼𝐶𝑎𝑇  are L-, N-, and T-type voltage-dependent Ca
2+ currents, 
respectively; 𝐼𝑁𝑎 is a voltage-dependent Na
+ current; 𝐼𝐾  is a delayed rectifier K
+ current; 𝐼𝐾𝐴 is an A-type 
voltage-dependent K+ current; 𝐼𝐾(𝐴𝑇𝑃) is an ATP-sensitive K
+ current; 𝐼𝐿  is a leak current. This model is 
described in detail in (Briant et al., 2018). In addition, we modelled the current due to the Na+-K+ pump 
(Na+/K+-ATPase), 𝐼𝑝𝑢𝑚𝑝. The equations describing this current are  
𝐼𝑝𝑢𝑚𝑝  =  
𝐼𝑝𝑢𝑚𝑝̅̅ ̅̅ ̅̅ ̅
1 + (
𝑘𝑚
[𝑁𝑎+]𝑖
⁄ )
𝑛 
as described in Canavier (1999). This current writes to the transmembrane Na+ and K+ currents in the NEURON 
environent, as follows: 
𝐼𝑁𝑎  =  3 · 𝐼𝑝𝑢𝑚𝑝  
𝐼𝐾  =  −2 · 𝐼𝑝𝑢𝑚𝑝 
To mimic reduced ATP supply to the Na+-K+ pump, we reduced the maximal pump current, 𝐼𝑝𝑢𝑚𝑝̅̅ ̅̅ ̅̅ ̅. 
 
Glucagon release was modelled by using the 4 variable system described by Yamada and Zucker (1992) and 
later simplified by Destexhe et al. (1994). In brief, the intracellular calcium concentration [𝐶𝑎2+] was modelled 
as the sum of calcium fluxes due to the total calcium current (𝐼𝐶𝑎 = 𝐼𝐶𝑎𝐿 + 𝐼𝐶𝑎𝑁 + 𝐼𝐶𝑎𝑇) and a calcium buffering 
term: 
 
𝑑[𝐶𝑎2+]
𝑑𝑡
=
2𝐼𝐶𝑎
𝐹𝑑 ∙ 𝑑
+
([𝐶𝑎2+]0 − [𝐶𝑎
2+])
𝜏
 (2) 
Here, calcium is buffered to [𝐶𝑎2+]0 with time-constant 𝜏, 𝐹𝑑 is Faradays constant and 𝑑 is the depth of the 
calcium domain. This calcium concentration drives a system of differential equations describing glucagon 
vesicle dynamics:  
 
𝑑[𝐹𝐴]
𝑑𝑡
= 𝑘𝑏([𝐹𝑚𝑎𝑥] − [𝐹𝐴] − [𝑉𝐴])[𝐶𝑎
2+]4 − 𝑘𝑢[𝐹𝐴] − 𝑘1[𝐹𝐴][𝑉] + 𝑘2[𝑉𝐴] (3) 
 
𝑑[𝑉𝐴]
𝑑𝑡
= 𝑘1[𝐹𝐴][𝑉] − (𝑘2 + 𝑘3)[𝑉𝐴] (4) 
 
𝑑[𝐺𝐶𝐺]
𝑑𝑡
= 𝑁𝑘3[𝑉𝐴] − 𝑘ℎ[𝐺𝐶𝐺] (5) 
Here, calcium ions are assumed to reversibly bind to a fusion protein 𝐹. Four calcium ions bind to this protein at 
a rate 𝑘𝑏, activating it. The concentration of activiated fusion protein is [𝐹𝐴], coming from a pool of inactivated 
proteins with concentration [𝐹𝑚𝑎𝑥]. The reverse process has an unbinding rate 𝑘𝑢. An activated fusion protein 
binds to a vesicle (𝑉) at a rate 𝑘1, activated it (𝑉𝐴). This process is reversible with unbind rate 𝑘2. The 
concentrations of inactivated and activated vesicles are [𝑉] and [𝑉𝐴], respectively. Destexhe et al. (1994) 
simplified this system by assuming that there exists an inexhaustible pool of inactivated vesicles, ready for 
activation. In particular, [𝑉] is constant and not depleted. This assumption is adopted. An activated vesicle is 
then able to fuse to the membrane of the cell, and release its contents. An activated vesicle releases 𝑁 molecules 
of glucagon (𝐺𝐶𝐺) at a rate 𝑘3. The concentration of glucagon released is [𝐺𝐶𝐺]. This is depleted in the 
extracellular space by diffusion, degradation and reuptake at a rate 𝑘ℎ. 
 
Statistical tests 
All data are reported as mean ± S.E.M., unless otherwise stated. Statistical significance was defined as p<0.05. 
All statistical tests were conducted in Prism5 (GraphPad Software, San Diego, CA). For two groupings, a t-test 
was conducted. If the data were non-parametric, a Mann-Whitney test was conducted. For more than two 
groupings, a one-way ANOVA was conducted. If there were two independent variables, a two-way ANOVA 
was conducted. If the data passed normality criteria (D’Agostino’s test of normality and Bartlett’s test of equal 
variances), a parametric test was conducted with the appropriate post hoc test (Tukey or Student Neumann 
Keuls). If the normality criteria were not met, a Kruskal–Wallis test with Dunn’s multiple comparison test was 
conducted. 
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